AZN

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.38
Percentage change 0.54	%

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM TQQQ DIHP DFIC FVD PVAL AVDE PPH QYLD

Scroll to Statements

Index	NDX	P/E	28.73	EPS (ttm)	2.49	Insider Own	0.01%	Shs Outstand	3.10B	Perf Week	2.71%
Market Cap	221.79B	Forward P/E	14.00	EPS next Y	5.11	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-3.02%
Enterprise Value	248.13B	PEG	2.52	EPS next Q	1.08	Inst Own	16.61%	Short Float	0.22%	Perf Quarter	10.24%
Income	7.77B	P/S	4.03	EPS this Y	10.05%	Inst Trans	1.25%	Short Ratio	1.48	Perf Half Y	7.41%
Sales	54.98B	P/B	5.40	EPS next Y	13.06%	ROA	7.45%	Short Interest	6.81M	Perf YTD	9.15%
Book/sh	13.23	P/C	41.11	EPS next 5Y	11.42%	ROE	19.81%	52W High	87.68 -18.43%	Perf Year	-8.02%
Cash/sh	1.74	P/FCF	19.34	EPS past 3/5Y	285.87% 34.63%	ROIC	11.28%	52W Low	61.24 16.78%	Perf 3Y	6.86%
Dividend Est.	1.61 (2.26%)	EV/EBITDA	13.74	Sales past 3/5Y	12.64% 17.27%	Gross Margin	72.58%	Volatility	1.43% 1.50%	Perf 5Y	33.75%
Dividend TTM	1.55 (2.17%)	EV/Sales	4.51	EPS Y/Y TTM	22.70%	Oper. Margin	20.63%	ATR (14)	1.20	Perf 10Y	119.64%
Dividend Ex-Date	Feb 21, 2025	Quick Ratio	0.70	Sales Y/Y TTM	15.48%	Profit Margin	14.14%	RSI (14)	53.04	Recom	1.37
Dividend Gr. 3/5Y	2.54% 2.10%	Current Ratio	0.90	EPS Q/Q	33.73%	SMA20	0.92%	Beta	0.36	Target Price	93.04
Payout	66.98%	Debt/Eq	0.77	Sales Q/Q	7.17%	SMA50	1.02%	Rel Volume	0.69	Prev Close	71.13
Employees	94300	LT Debt/Eq	0.68	Earnings	Jul 29 BMO	SMA200	0.79%	Avg Volume	4.61M	Price	71.51
IPO	May 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.52% -1.60%	Trades		Volume	819,473	Change	0.54%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Today 09:40AM	Here's Why Astrazeneca (AZN) is a Strong Value Stock (Zacks)
08:50AM	AstraZeneca shares show signs of life after successful trials of hypertension drug (MarketWatch)
07:00AM	Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension (Business Wire)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
Jul-12-25 09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
08:30PM	Loading…
Jul-11-25 08:30PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
Jul-09-25 10:25AM	Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal (Insider Monkey)
09:19AM	GSK's Specialty Medicines Unit on a Strong Footing: Here's Why (Zacks)
09:09AM	AstraZeneca PLC (AZN) Partners Modella AI for AI Drug Development (Insider Monkey)
06:17AM	The Zacks Analyst Blog Highlights T-Mobile US, AstraZeneca and Comcast (Zacks)
Jul-08-25 04:17PM	Top Analyst Reports for T-Mobile, AstraZeneca & Comcast (Zacks)
10:43AM	AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth? (Zacks)
Jul-07-25 05:06PM	IonQ Is Still 'in the Early Innings.' Why It's Positioned to Become a Quantum Leader. (Barrons.com)
08:52AM	SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca (Zacks)
Jul-06-25 04:01AM	Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug (Insider Monkey)
09:00AM	Loading…
Jul-04-25 09:00AM	How Much of Your Portfolio Should Be in International Stocks? (The Wall Street Journal)
08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-03-25 06:26PM	Why AstraZeneca Stock Got Thumped on Thursday (Motley Fool)
01:56PM	Lucid, Alibaba, AstraZeneca & Summit: Trending Tickers (Yahoo Finance Video)
12:31PM	Report: Summit in talks for $15 billion partnership with AstraZeneca (CNBC TV)
10:58AM	Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal (Investing.com)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-02-25 05:09PM	London's IPO Crisis Worsens--and AstraZeneca Could Join the Exodus (GuruFocus.com)
09:07AM	Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:11AM	What's Fueling Tempus AI's Explosive Sales Growth? (Zacks)
Jul-01-25 06:15PM	Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors (Zacks)
05:18PM	Why AstraZeneca Stock Topped the Market on Tuesday (Motley Fool)
03:24PM	AstraZeneca Gains as U.S. Listing Move Considered (GuruFocus.com)
11:57AM	Constellation Brands, AstraZeneca, casino stocks: Trending Tickers (Yahoo Finance Video)
11:12AM	Loading…
11:12AM	AstraZeneca stock rises amid reports CEO favors US listing move (Investing.com)
09:35AM	Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth (Zacks)
Jun-30-25 11:31AM	AstraZeneca (AZN) Announces Strategic Research Collaboration with CSPC Pharmaceuticals (Insider Monkey)
Jun-28-25 06:35AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-26-25 10:15AM	Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. (Investor's Business Daily)
09:47AM	Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE? (Zacks)
09:30AM	Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Jun-25-25 06:30AM	AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer (The Daily Upside)
04:09AM	AstraZeneca Presents Positive Phase I/II Data for Surovatamig in B-cell ALL at EHA 2025 (Insider Monkey)
Jun-24-25 09:56AM	Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip? (Zacks)
09:45AM	Here's Why Astrazeneca (AZN) is a Strong Growth Stock (Zacks)
09:04AM	FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer (Zacks)
08:22AM	Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth? (Zacks)
07:00AM	DATROWAY approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer (Business Wire)
05:39AM	FDA approves AstraZeneca and Daiichi Sankyos Datroway for NSCLC (Pharmaceutical Technology)
04:07AM	Approval for AstraZenecas Datroway drug a minor positive for shares: JPMorgan (Investing.com)
02:32AM	AstraZenecas Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. (The Wall Street Journal)
02:15AM	US approves AstraZeneca, Daiichi's treatment for lung cancer (Reuters)
Jun-23-25 03:00PM	TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now? (Zacks)
09:40AM	Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term (Zacks)
Jun-20-25 09:50AM	Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term (Zacks)
Jun-19-25 09:47AM	Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth? (Zacks)
Jun-18-25 10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
Jun-17-25 05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
02:39PM	Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards? (Zacks)
Jun-16-25 06:15PM	Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
08:29AM	EHA 2025: AstraZenecas surovatamig is potential next-gen BiTE for R/R B-ALL (Pharmaceutical Technology)
Jun-15-25 05:39AM	AstraZeneca's ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer (Insider Monkey)
Jun-13-25 12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
12:19PM	AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal (Pharmaceutical Technology)
12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
05:29AM	AstraZeneca Enters Deal With CSPC Pharma Valued at Up to $5.33 Billion (The Wall Street Journal)
05:11AM	The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies (Zacks)
04:40AM	AstraZeneca signs AI research deal with China's CSPC for chronic diseases (Reuters)
Jun-12-25 04:43PM	Top Stock Reports for Microsoft, AstraZeneca & BlackRock (Zacks)
10:21AM	PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds (Zacks)
Jun-11-25 10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
Jun-10-25 06:15PM	Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know (Zacks)
03:00PM	Is IonQ a Better Quantum Computing Stock to Buy Than D-Wave? (Zacks)
10:50AM	Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants (Zacks)
10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks)
10:10AM	RFK Jr. removes CDC vaccine panel members: What to know (Yahoo Finance Video)
Jun-09-25 03:00PM	Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? (Zacks)
12:39PM	AstraZeneca and Pangaea partner for AI detection of hypophosphatasia (Medical Device Network)
11:33AM	IonQ Stock Unveils UK Oxford Ionics Acquisition, Nvidia Quantum Collaboration (Investopedia)
11:08AM	Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point. (Barrons.com)
11:00AM	Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season (Benzinga)
07:23AM	IonQ To Buy Oxford Ionics In $1 Billion Deal As Acquisition Spree Continues (Investor's Business Daily)
04:57AM	EC approves AstraZenecas acalabrutinib combo for CLL (Pharmaceutical Technology)
Jun-06-25 11:31AM	Why Is Techne (TECH) Down 3% Since Last Earnings Report? (Zacks)
09:45AM	Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term (Zacks)
09:12AM	Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? (Zacks)
Jun-05-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
02:00AM	Global Markets Are On a Tear. These Stocks in Europe and Japan Are Still Bargains. (Barrons.com)
Jun-04-25 12:03PM	Daiichi Sankyo struck gold with ADC cancer drugs. Its new CEO has to figure out whats next. (BioPharma Dive)
Jun-02-25 06:15PM	Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
01:15PM	AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO (Benzinga)
12:53PM	ASCO25: AstraZenecas novel trial design for camizestrant pays off in breast cancer (Clinical Trials Arena)
11:23AM	AstraZeneca CEO Pascal Soriot on breast cancer drug trial (CNBC TV)
09:23AM	AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment (CNBC TV)
08:00AM	How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma (Investor's Business Daily)
08:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial (Business Wire)
07:22AM	Experimental AstraZeneca pill helps cut risk of breast cancer progression (CNBC TV)
04:00AM	Enhertu potential broadens as new data point to frontline breast cancer role (BioPharma Dive)
Jun-01-25 08:05AM	IMFINZI (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial (Business Wire)
08:03AM	Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk (Reuters)
08:00AM	Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial (Business Wire)
07:10AM	A funding flashpoint, Pfizers $1B poster and AstraZeneca advertising (BioPharma Dive)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc ADR

Upgrade your FINVIZ experience